Martifer quer distribuir 4 milhões em dividendos antes da OPA

[Luka!]

Endocyte's (ECYT) cancer treatment offers big potential for investors willing to wait and take a chance.

The company's SMDC is an innovative technology that could change the efficacy of many chemotherapy drugs that exist today.
The oncology market is projected to reach $110 billion by 2018, any sliver of this market for Endocyte could be monumental for this small-cap company.
Endocyte has a bolus of products in the pipeline, of which many of them could produce strong revenues.
Endocyte is currently valued at about $220 million. As of the third-quarter 2014, the company had $211.4 million in cash/equivalents. Investors can buy the future revenue for free.

Take-Home Message
Endocyte is a small biopharmaceutical company that is working on pioneering disease treatment using SMDCs. If successful, SMDCs could revolutionize cancer treatment by increasing efficacy while reducing the actual dosage. This will reduce costs and side effects of chemotherapy for patients. Endocyte has multiple products at various stages in development and clinical trials, and based on my estimations more than likely will not have anything to market before 2017. The company currently has plenty of cash on the balance sheet to fund operations through 2017 and beyond. When looking at the current valuation, the company is trading slightly higher than the amount of cash on hand. As of now, the company does not have a reliable revenue source, but based on the fact that the company is valued more or less in line with the cash on the balance sheet, I think Endocyte could fill a spot in a portfolio reserved for a risky investment. If the company is able to get its products to market, the oncology market has plenty of revenue and profits to make this a big return.